Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | ACP3 | P15309 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756292 | 0.70 | LMNA (0.45) | LMNAKMT2AMEN1RIPK1POLB | |
| SCHEMBL11588095 | 0.69 | LMNA (0.43) | LMNAKMT2AMEN1RIPK1POLB | |
| SCHEMBL11590303 | 0.69 | LMNA (0.43) | LMNAKMT2AMEN1RIPK1POLB | |
| SCHEMBL10417502 | 0.68 | KCNN4 (0.47) | LMNAKMT2AKCNN4 | |
| SCHEMBL6738852 | 0.67 | AOC3 (0.41) | LMNAKMT2AMEN1RIPK1KCNN4 | |
| SCHEMBL7912705 | 0.67 | MAPT (0.36) | LMNAKMT2AKCNN4 | |
| SCHEMBL8403351 | 0.67 | KDM4E (0.43) | LMNAKMT2AACP3 | |
| SCHEMBL8587190 | 0.67 | KDM4E (0.43) | LMNAKMT2AACP3 | |
| SCHEMBL15233759 | 0.67 | KMT2A (0.35) | KMT2AHTTKCNN4 | |
| SCHEMBL934392 | 0.66 | MAPK1 (0.38) | THRBKMT2AKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | disclosed |
| US-6448373-B1 | INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0739351-B1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | LMNA 2734/4885THRB 4419/4885KMT2A 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.